Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents
Medical Laboratory Technology Journal · 2020
DOI: 10.31964/mltj.v0i0.281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Laboratory Technology Journal, 2020. Verfasst von Semih Başcı und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Significant improvements in the prognosis of Multiple Myeloma(MM) have recently observed in the era of novel agents. Induction treatment, including new agents followed by conditioning regimen and upfront autologous stem cell transplantation(ASCT), has been accepted as the standard treatment approach for newly diagnosed eligible MM patients. Despite novel agents, upfront ASCT is still superior to conventional chemotherapy alone. Previous studies revealed that the duration between ASCT and relapse had predicted overall survival(OS), and meantime, it was widely used to determine the potential benefit from a second ASCT. However, the majority of the data collected reflects the treatment modalities before novel agents. In this study, we aimed to investigate the impact of post-transplantation early relapse(ER) on survival in the era of novel agents. The results of 155 MM patients that underwent ASCT at our center between January 2010 and May 2018 were analyzed retrospectively. The median follow-up duration was 20 months in the ER group, 27 months in the non-ER group, and 24 months in all patients. 33.3% of patients in the ER group and 71.4% of patients in the non-ER group were alive at the time of analysis. Median OS was 20.77±3.66 months in the ER group and 40.89±4.21 months in the non-ER group. We found a statistically significant relationship between the ER and the poor OS (p:
Zitieren
APA
Başcı, S., Yiğenoğlu, T. N., Ulu, B. U., Bakırtaş, M., Şahin, D., Darçın, T., Yıldız, J., Merdin, A., Baysal, N. A., İskender, D., Çakar, M. K., Dal, M. S., Hacıbekiroğlu, T., & Altuntaş, F. (2020). Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents. Medical Laboratory Technology Journal. https://doi.org/10.31964/mltj.v0i0.281
Vancouver
Başcı S, Yiğenoğlu TN, Ulu BU, Bakırtaş M, Şahin D, Darçın T, et al. Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents. Medical Laboratory Technology Journal. 2020. doi:10.31964/mltj.v0i0.281
BibTeX
@article{Bac2020,
author = {Başcı, Semih and Yiğenoğlu, Tuğçe Nur and Ulu, Bahar Uncu and Bakırtaş, Mehmet and Şahin, Derya and Darçın, Tahir and Yıldız, Jale and Merdin, Alparslan and Baysal, Nuran Ahu and İskender, Dicle and Çakar, Merih Kızıl and Dal, Mehmet Sinan and Hacıbekiroğlu, Tuba and Altuntaş, Fevzi},
title = {Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents},
journal = {Medical Laboratory Technology Journal},
year = {2020},
doi = {10.31964/mltj.v0i0.281}
}
EUVIMED